drugset / Trial / NCT03862651

Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE)

NCT03862651

Phase 2 Unknown 140 enrolled Ospedale Santa Croce-Carle Cuneo
RandomizedSingle-groupDouble-blindTreatment

Summary

The MONET BRIDGE study is designed to assess the use of cangrelor as a platelet-inhibiting bridge for patients who discontinue DAPT before cardiac and non cardiac surgery within 12 months from coronary stent implantation. It seeks to determine if initiation of a prolonged cangrelor infusion maintains effective platelet inhibition after discontinuation of P2Y12 and whether a cangrelor infusion before cardiac and non cardiac procedures is safe.

Timeline

Start
2019-06-01
Primary completion
2020-12-31
Completion
2021-01-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cangrelor Small molecule 0.75 ug/kg Intravenous